Phospho-NTRK1 (Y701) Antibody
Description
Introduction to Phospho-NTRK1 (Y701) Antibody
Phospho-NTRK1 (Y701) Antibody is a specialized immunological reagent designed to detect NTRK1 (TrkA) protein exclusively when phosphorylated at tyrosine residue 701 . This antibody serves as a crucial tool for investigating neurotrophin signaling pathways, which play vital roles in neuronal development, survival, and function . The ability to specifically detect phosphorylated NTRK1 at Y701 provides researchers with precise information about the activation status of this important receptor tyrosine kinase .
The development of phospho-specific antibodies has revolutionized the study of signal transduction pathways by allowing researchers to monitor specific phosphorylation events that regulate protein activity. In the case of NTRK1, phosphorylation at Y701 represents a critical post-translational modification that occurs during receptor activation following neurotrophin binding or in certain pathological conditions such as oncogenic fusion events . This phosphorylation event is essential for downstream signaling and biological functions of NTRK1.
Unlike general NTRK1 antibodies that detect total protein regardless of activation state, Phospho-NTRK1 (Y701) Antibody exclusively recognizes the activated form of the receptor . This specificity makes it an invaluable tool for researchers studying the dynamics of NTRK1 activation in various experimental and clinical contexts.
Applications and Usage Guidelines
Phospho-NTRK1 (Y701) antibodies demonstrate versatility across multiple experimental applications, making them valuable tools for diverse research objectives. The following table outlines common applications and recommended usage parameters:
In Western blot applications, the antibody typically detects a band corresponding to the molecular weight of NTRK1 (approximately 87 kDa) . The specificity can be validated through peptide competition assays, where pre-incubation with the phosphorylated peptide blocks antibody binding . Additional validation can be performed using lysates from cells treated with phosphatase inhibitors (to preserve phosphorylation) or TRK inhibitors (to reduce phosphorylation) .
For immunohistochemical applications, the antibody has been successfully used to detect phosphorylated NTRK1 in various tissues, including brain samples . Appropriate controls include blocking with the phosphopeptide and comparing staining patterns with known NTRK1-expressing and non-expressing tissues .
Cell-based ELISA assays offer a high-throughput approach for screening compounds that may affect NTRK1 phosphorylation status, making this application particularly valuable for drug discovery efforts targeting NTRK1 .
NTRK1 Biology and Signaling Pathway
NTRK1 (TrkA) functions as a high-affinity receptor for Nerve Growth Factor (NGF), playing crucial roles in neuronal development, survival, differentiation, and function . The receptor consists of an extracellular domain that binds NGF, a transmembrane region, and an intracellular tyrosine kinase domain that mediates downstream signaling .
Upon NGF binding, NTRK1 undergoes dimerization and autophosphorylation at multiple tyrosine residues, including Y701 . These phosphorylation events create docking sites for adapter proteins that initiate various signaling cascades. The activated NTRK1 receptor triggers several downstream pathways:
-
ERK/MAPK pathway: Phosphorylated NTRK1 activates ERK1/2 through a signaling cascade, promoting cell proliferation, differentiation, and survival .
-
PI3K/Akt pathway: NTRK1 activation leads to phosphorylation of Akt, enhancing cell survival mechanisms and preventing apoptosis .
-
PLCγ pathway: Phosphorylated NTRK1 recruits and activates PLCγ, leading to calcium signaling and protein kinase C activation .
The phosphorylation of Y701, specifically, is critical for the functional activity of NTRK1, making antibodies that recognize this modification valuable tools for studying NTRK1 activation status . In experimental settings, researchers have demonstrated that inhibition of NTRK1 phosphorylation at Y701 blocks downstream signaling events, confirming the importance of this specific phosphorylation site .
Interestingly, NTRK1 signaling can also be modulated by other factors, including adenosine acting through adenosine 2A receptors, which can transactivate Trk receptors through a unique signaling mechanism . This crosstalk between different signaling pathways adds complexity to NTRK1 biology and highlights the importance of tools that can specifically monitor receptor activation status.
Clinical and Research Significance
NTRK1 has garnered significant attention in recent years due to the discovery of NTRK gene rearrangements and fusions in various cancer types . These genetic alterations result in constitutively active NTRK proteins that drive tumor growth and progression, making them important therapeutic targets .
Phospho-NTRK1 (Y701) antibodies serve critical functions in multiple research and clinical contexts:
-
Cancer research: These antibodies enable detection of activated NTRK1 in tumors harboring NTRK gene fusions or other alterations . Research has identified various fusion partners for NTRK1, including TPM3, CD74, LMNA, TPR, IRF2BP2, and others, across different cancer types .
-
Neuroscience research: The antibodies facilitate studies of neurotrophin signaling in neuronal development, survival, and plasticity . This application is particularly important given the central role of NTRK1 in mediating NGF effects on neurons.
-
Drug development: Phospho-NTRK1 (Y701) antibodies are valuable tools for evaluating the efficacy of TRK inhibitors by monitoring changes in receptor phosphorylation status . Several TRK inhibitors have been developed for cancer therapy, including larotrectinib and entrectinib .
-
Diagnostic applications: While still primarily research tools, these antibodies hold potential for diagnostic applications in identifying patients who might benefit from TRK inhibitor therapy .
The frequency of NTRK1 alterations varies by tumor type, with notable occurrences in non-small cell lung cancer (NSCLC), colorectal cancer, papillary thyroid cancer, and certain sarcomas . In lung cancer specifically, NTRK1 fusions have been identified in approximately 0.1-3% of cases, and patients with these alterations have shown significant responses to TRK inhibitors .
Validation and Quality Control
Rigorous validation is essential for ensuring the specificity and reliability of Phospho-NTRK1 (Y701) antibodies. Manufacturers typically employ multiple validation strategies:
-
Peptide specificity testing: Comparing reactivity with phosphorylated versus non-phosphorylated peptides to confirm phospho-specificity . This often involves ELISA-based assays that demonstrate preferential binding to the phosphorylated peptide.
-
Western blot validation: Demonstrating specific detection of phosphorylated NTRK1 in appropriate cell lysates . For example, Abnova's PAB29637 antibody has been validated using mouse brain lysates, showing specific detection of phosphorylated NTRK1 that can be blocked with the immunizing peptide .
-
Peptide competition assays: Showing that the specific phosphopeptide can block antibody binding in Western blot or immunohistochemistry applications . This provides strong evidence for epitope-specific binding.
-
Cross-reactivity testing: Ensuring minimal cross-reactivity with other phosphorylated proteins . This is particularly important given the structural similarities between different receptor tyrosine kinases.
The molecular weight of NTRK1 on Western blots is typically around 87 kDa, though this may vary depending on post-translational modifications such as glycosylation . Signal specificity can be further validated using samples treated with phosphatase inhibitors (to preserve phosphorylation) or TRK inhibitors such as KRC-108 (to reduce phosphorylation) .
For cell-based assays, validation often includes demonstrating reduced signal following treatment with specific inhibitors or following knockdown of NTRK1 expression . Additionally, comparison of staining patterns between tissues known to express NTRK1 (e.g., neuronal tissues) and those with low or no expression provides further validation of antibody specificity .
Product Specs
Target Background
The NTRK1 gene encodes TrkA, a receptor tyrosine kinase crucial for central and peripheral nervous system development and maturation. TrkA regulates the proliferation, differentiation, and survival of sympathetic and sensory neurons. It exhibits high affinity for nerve growth factor (NGF), its primary ligand, and can also bind and be activated by neurotrophin-3 (NTF3). While NTF3 promotes axonal extension via TrkA, it does not influence neuronal survival. NGF binding induces TrkA homodimerization, autophosphorylation, and activation, leading to the recruitment and phosphorylation of downstream effectors, including SHC1, FRS2, SH2B1, SH2B2, and PLCG1. These effectors regulate overlapping signaling cascades governing cell survival and differentiation. Specifically, TrkA activates:
- A GRB2-Ras-MAPK cascade (via SHC1 and FRS2) that regulates cell differentiation and survival.
- NF-κB activation and transcription of survival-related genes (via PLCG1).
- A Ras-PI3 kinase-AKT1 cascade (via SHC1 and SH2B1) that also regulates survival.
In the absence of ligand and activation, TrkA may promote cell death, highlighting the dependence of neuronal survival on trophic factors. NGF-resistant TrkA constitutively activates AKT1 and NF-κB but fails to activate the Ras-MAPK cascade. This resistance antagonizes the anti-proliferative NGF-TrkA signaling that typically promotes neuronal precursor differentiation. The TrkA-III isoform promotes angiogenesis and exhibits oncogenic activity when overexpressed.
NTRK1 Gene Function: Relevant Research
- Identification of novel compound heterozygous NTRK1 variants (c.632T>A and c.1253_1254delTC) in Chinese identical twins with Congenital Insensitivity to Pain and Anhidrosis (CIPA). PMID: 30461622
- Rutin preconditioning ameliorates cerebral ischemia/reperfusion injury in ovariectomized rats via ER-mediated BDNF-TrkB and NGF-TrkA signaling. PMID: 29420916
- The TrkA peptide competitively binds metals, similar to analogous peptides due to the N-terminal domain of NGF. This suggests potential effects of metal ions on NGF activity and its receptor. PMID: 30103559
- The LMNA-NTRK1 fusion was identified as the driver of tumorigenesis and metastasis, with crizotinib demonstrating therapeutic efficacy. PMID: 30134855
- Lipofibromatosis-like tumors represent a novel entity of NTRK1-associated neoplasms. PMID: 29958731
- System xC(-)-mediated TrkA activation is a potential therapeutic target for cancer pain. PMID: 29761734
- Identification of known and novel NTRK1 mutations in CIPA pedigrees, expanding the mutation spectrum and providing insights into genotype-phenotype correlations. PMID: 30201336
- Report of 27 NTRK1 mutations from a CIPA cohort, including 15 novel mutations. PMID: 29770739
- NTRK1 upregulation in 80% of head and neck squamous cell carcinoma tissues. PMID: 29904026
- TrkA expression in approximately 1.6% of solid tumors is often associated with NTRK1 gene rearrangements or copy number gain. PMID: 29802225
- Polymorphisms in NTRK1 influence pain sensitivity in young Han Chinese women. PMID: 29054434
- Development of a model for acquired resistance to NTRK inhibitors and identification of cabozantinib as a potential overcoming strategy. PMID: 28751539
- TrkA's significant role in the pathogenesis of NPM-ALK(+) T-cell lymphoma. PMID: 28557340
- Frequent BRCA2, EGFR, and NTRK1/2/3 mutations in mismatch repair-deficient colorectal cancers, suggesting personalized medicine approaches. PMID: 28591715
- Report of a novel deletional mutation in NTRK1, expanding the spectrum of known mutations. PMID: 28981924
- Identification and characterization of four novel NTRK1 mutations (IVS14+3A>T, p.Ser235*, p.Asp596Asn, and p.Leu784Serfs*79) using mRNA splicing and NTRK autophosphorylation assays. PMID: 28177573
- A novel mechanism for TRAIL-induced apoptosis in TrkAIII-expressing neuroblastoma cells involving SHP/Src-mediated crosstalk between the TRAIL receptor and TrkAIII signaling pathways. PMID: 27821809
- Variation in plasmatic monocytic TrkA expression during dementia progression. PMID: 27802234
- TrkA detection in 20% of thyroid cancers (compared to none in benign samples), associated with lymph node metastasis and suggesting involvement in tumor invasiveness. PMID: 29037860
- Report of phenotypes and novel/recurrent NTRK1 mutations in two Chinese CIPA patients. PMID: 28192073
- Complete abolition of TRKA kinase activity is not the sole pathogenic mechanism underlying hereditary sensory and autonomic neuropathy type IV (HSAN IV). PMID: 27676246
- Nine patients from nine unrelated families with HSAN IV due to various NTRK1 mutations (five novel). PMID: 28328124
- Review highlighting the bulky phenylalanine gatekeeper in TrkA, TrkB, and TrkC kinase domains, resulting in a less attractive binding site for antineoplastic kinase inhibitors. PMID: 28215291
- Pan-Trk immunohistochemistry as a time-efficient screen for NTRK fusions, especially in driver-negative advanced malignancies and secretory carcinoma/congenital fibrosarcoma cases. PMID: 28719467
- Analysis revealing a variant's influence on NTRK1 mRNA splicing, leading to a non-functional gene product. PMID: 27184211
- NTRK fusions in a subset of young patients with mesenchymal or sarcoma-like tumors at low frequency. PMID: 28097808
- Identification of a novel nonsense and a known splice-site mutation in NTRK1 associated with CIPA in two siblings. PMID: 28345382
- NTRK1 gene fusion in spitzoid neoplasms, resulting in tumors with Kamino bodies and specific cellular arrangements. PMID: 27776007
- NTRK1 oncogenic activation through gene fusion defines a distinct subset of soft tissue tumors resembling lipofibromatosis, but with cytologic atypia and a neural immunophenotype. PMID: 27259011
- Review highlighting treatment options and clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations. PMID: 27912827
- ShcD binding to active Ret, TrkA, and TrkB neurotrophic factor receptors primarily via its phosphotyrosine-binding (PTB) domain. PMID: 28213521
- TrkA misfolding and aggregation due to certain CIPA mutations disrupt autophagy homeostasis, causing neurodegeneration. PMID: 27551041
- USP36's role extends beyond TrkA, interfering with Nedd4-2-dependent Kv7.2/3 channel regulation. PMID: 27445338
- TrkA expression's association with tumor progression and poor survival in gastric cancer patients. PMID: 26459250
- High NTRK1 expression in association with colon cancer. PMID: 26716414
- TrkA immunohistochemistry as an effective initial screening method for NTRK1 rearrangement detection. PMID: 26472021
- Identification of GGA3 as a key player in DXXLL-mediated endosomal sorting targeting TrkA to the plasma membrane, prolonging Akt signaling and survival responses. PMID: 26446845
- p.G595R and p.G667C TRKA mutations driving acquired resistance to entrectinib in colorectal cancers with NTRK1 rearrangements. PMID: 26546295
- TrkA signaling and EGFR signaling pathways' significant and differential enrichment by miR-96 allele-specific target genes in progressive hearing loss. PMID: 26564979
- Report of a novel variant of myo/haemangiopericytic sarcoma with recurrent NTRK1 gene fusions. PMID: 26863915
- TrkA as a potential oncogene in malignant melanoma, suggesting the NGF-TrkA-MAPK pathway's role in balancing neoplastic transformation and anti-proliferative response. PMID: 26496938
- IL-13's role in conferring epithelial cell responsiveness to NGF by regulating NTRK1 levels, potentially contributing to allergic inflammation. PMID: 25389033
- Cbl-b's role in limiting NGF-TrkA signaling to control neurite length. PMID: 25921289
- Higher NTRK1 mRNA expression in low-grade gliomas compared to high-grade gliomas and control samples, with poor survival associated with NTRK1 mRNA expression. Promoter methylation does not regulate NTRK1 genes in glioma. PMID: 24840578
- NTRK1 gene translocations as recurring events in colorectal cancer, albeit at a low frequency (around 0.5%). PMID: 26001971
- Implications of findings for understanding the less malignant neuroblastoma phenotype associated with NTRK1 expression and potential development of new therapeutic strategies. PMID: 25361003
- Bex3 protein's regulation of TrkA expression in neurons at the gene promoter level. PMID: 25948268
- Unlikely causative role for M379I and R577G NTRK1 mutations in melanoma development. PMID: 24965840
- Association of increased NTRK1 expression with spontaneous abortions. PMID: 24825909
- Neurotrophin function through TrkC and TrkA tyrosine kinase receptors. PMID: 24603864
Q&A
What is NTRK1 and why is its phosphorylation status important?
NTRK1 encodes the TRKA receptor tyrosine kinase, which plays a critical role in cellular signaling pathways. Phosphorylation of NTRK1/TRKA is essential for its activation and downstream signaling. When activated, NTRK1 undergoes autophosphorylation at specific tyrosine residues (including Y490, Y674, and Y675), which leads to activation of downstream pathways such as ERK via phosphorylation . This phosphorylation-dependent activation is fundamental to understanding NTRK1's role in both normal cellular function and disease states, particularly in oncogenic contexts.
How do NTRK1 gene fusions contribute to cancer development?
NTRK1 gene fusions occur when the kinase domain of NTRK1 joins with various partner genes. These fusion events, such as MPRIP-NTRK1 and CD74-NTRK1, have been identified in lung cancer patients without other known genetic alterations . These fusions lead to constitutive TRKA kinase activity, meaning the kinase becomes permanently activated without normal regulatory control. This constitutive activation makes these fusions oncogenic, driving uncontrolled cell growth and proliferation . Approximately 3.3% of lung cancer patients without known oncogenic alterations demonstrate evidence of NTRK1 gene fusions .
What methodologies are available for detecting NTRK1 phosphorylation?
Multiple methods can be employed to detect NTRK1 phosphorylation in research settings:
-
Western blotting: Using phospho-specific antibodies that recognize specific phosphorylated residues of NTRK1
-
Flow cytometry: For intracellular detection of phosphorylated NTRK1 in cell populations
-
Fluorescence in situ hybridization (FISH): For detecting chromosomal rearrangements within the NTRK1 gene
-
Targeted next-generation sequencing (NGS): Can detect gene fusion events involving NTRK1
When selecting a method, researchers should consider the specific research question, available sample types, and required sensitivity.
How can I validate the specificity of phospho-NTRK1 antibodies in my experimental system?
Validating phospho-specific antibodies requires a systematic approach:
-
Positive and negative controls: Use cell lines known to express NTRK1 (like CUTO-3 cells) treated with and without activation stimuli or inhibitors
-
Phosphatase treatment: Treat half of your positive sample with lambda phosphatase to remove phosphorylation and confirm loss of signal
-
Knockout/knockdown validation: Use NTRK1 knockout or knockdown cells to confirm specificity
-
Stimulation experiments: Stimulate cells with factors known to induce NTRK1 phosphorylation and observe increased signal
-
Inhibition experiments: Treat cells with TRKA kinase inhibitors to observe reduction in phosphorylation signal
A truly specific phospho-NTRK1 antibody should show signal only in positive controls, with significant reduction following phosphatase treatment or kinase inhibition.
What are optimal experimental conditions for detecting NTRK1 phosphorylation in different sample types?
| Sample Type | Lysis Buffer | Recommended Method | Special Considerations |
|---|---|---|---|
| Cell Lines | RIPA with phosphatase inhibitors | Western blot/Flow cytometry | Quick processing at 4°C essential |
| Tissue Samples | RIPA with protease/phosphatase inhibitors | Western blot/IHC | Flash freeze samples immediately |
| Patient-derived Xenografts | Tissue-specific buffers | Western blot/IHC/Flow cytometry | Standardize time from collection to fixation |
| Clinical Specimens | Phosphate buffers with inhibitor cocktails | FISH/NGS | Limited material requires optimization |
For all samples, remember that phosphorylation is labile and can be rapidly lost during sample preparation. Immediate addition of phosphatase inhibitors and processing on ice are critical for preserving phosphorylation status.
How do NTRK1 fusion proteins differ from wild-type NTRK1 in terms of phosphorylation and signaling?
NTRK1 fusion proteins demonstrate significant differences from wild-type NTRK1:
-
Constitutive phosphorylation: Fusion proteins like MPRIP-NTRK1 and CD74-NTRK1 show constitutive autophosphorylation at critical tyrosine residues without ligand stimulation
-
Altered localization: The fusion partner can change the subcellular localization of the kinase domain. For example, CD74-NTRK1 is predicted to be localized in the plasma membrane
-
Dimerization mechanisms: Many 5' fusion partners (like MPRIP) contain coiled-coil domains that mediate dimerization and consequently activation of the TRKA kinase domain
-
Downstream signaling: While wild-type NTRK1 signaling is tightly regulated, fusion proteins activate multiple downstream pathways including ERK, PI3K, and AKT constitutively
-
Drug sensitivity: NTRK1 fusion proteins may show differential sensitivity to TRK inhibitors compared to wild-type NTRK1, which has important implications for therapeutic targeting
What techniques can be used to identify and characterize novel NTRK1 fusion partners in patient samples?
For identifying novel NTRK1 fusion partners:
-
Targeted NGS: Using specific panels designed to detect gene rearrangements involving NTRK1
-
FISH assays: Custom-designed break-apart FISH probes can detect chromosomal rearrangements within the NTRK1 gene
-
RT-PCR followed by Sanger sequencing: For confirmation of exon junctions and mRNA expression
-
RNA-seq: To identify novel fusion transcripts involving NTRK1
-
Protein isolation and mass spectrometry: For direct identification of fusion proteins
For characterization of identified fusions:
-
Cloning of the entire cDNA: Essential for functional studies
-
Expression in model systems: To verify oncogenic potential
-
Phosphorylation analysis: Western blotting for autophosphorylation at critical TRKA tyrosine residues
-
Inhibitor sensitivity testing: To evaluate potential therapeutic approaches
Why might I observe inconsistent results when detecting phosphorylated NTRK1 in my samples?
Inconsistent results with phospho-NTRK1 detection can stem from several factors:
-
Sample handling: Phosphorylation is highly labile and can be lost during improper sample handling. Always process samples quickly at 4°C with phosphatase inhibitors.
-
Antibody specificity: Not all phospho-specific antibodies have equal specificity. Validate your antibody with appropriate controls, including phosphatase treatment and NTRK1-null samples.
-
Cell/tissue heterogeneity: In mixed populations, varying levels of NTRK1 expression can affect detection sensitivity. Consider enrichment methods or single-cell approaches.
-
Temporal dynamics: NTRK1 phosphorylation can be transient. Carefully optimize time points for analysis after stimulation.
-
Fixation artifacts: For IHC or flow cytometry, different fixation methods can affect epitope accessibility. Compare multiple fixation protocols to determine optimal conditions.
How can I differentiate between wild-type NTRK1 phosphorylation and NTRK1 fusion protein activity?
Differentiating between wild-type and fusion protein activity requires strategic experimental design:
-
Phosphorylation kinetics: Wild-type NTRK1 typically shows transient phosphorylation following ligand stimulation, while fusion proteins demonstrate constitutive phosphorylation
-
Molecular weight analysis: Western blotting can differentiate between wild-type NTRK1 and fusion proteins based on molecular weight differences
-
Inhibitor sensitivity profiling: Some TRK inhibitors show differential activity against wild-type versus fusion proteins
-
Fusion-specific antibodies: If available, antibodies recognizing the fusion junction can specifically detect fusion proteins
-
Subcellular localization: Immunofluorescence can reveal altered localization patterns of fusion proteins compared to wild-type NTRK1
How can phospho-NTRK1 antibodies be used to evaluate TRK inhibitor efficacy in research models?
Phospho-NTRK1 antibodies serve as crucial tools for evaluating TRK inhibitor efficacy:
-
Dose-response analysis: Western blotting with phospho-NTRK1 antibodies can measure inhibition of TRKA autophosphorylation across a range of inhibitor concentrations
-
Time-course experiments: Monitoring the duration of inhibition can reveal the pharmacodynamic properties of different inhibitors
-
In vivo efficacy: Immunohistochemistry with phospho-NTRK1 antibodies on tumor sections from treated animals can confirm target engagement
-
Resistance mechanisms: Changes in phosphorylation patterns following development of resistance can reveal adaptive mechanisms
-
Patient-derived models: Testing inhibitors on patient-derived xenografts or organoids can predict clinical responses when evaluated with phospho-NTRK1 antibodies
What are the key considerations when developing assays to detect NTRK1 gene fusions in clinical research?
Developing reliable clinical assays for NTRK1 gene fusions requires attention to several factors:
-
Assay sensitivity: NTRK1 fusions can be rare events (approximately 3.3% in certain lung cancer populations) . Assays must be highly sensitive to detect these rare events.
-
Multiple detection methods: Combining complementary techniques improves detection reliability:
-
Sample quality considerations: Clinical samples often have variable quality and quantity of nucleic acids. Assays should be robust to these variations.
-
Validation cohorts: Assays should be validated using samples with known NTRK1 fusion status, including a range of fusion partners.
-
Controls: Include positive controls (samples with confirmed NTRK1 fusions) and negative controls (samples without fusions) in each assay run.
